Search research articles
Contact Us
Filters
Showing results (191-200 of 219) with videos related to
Page
of 22
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2009
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
S Pecorelli, I Ray-Coquard, O Tredan, et al.
Brain, Behavior, and Immunity
|
May 1, 2025
Exercise-induced β<sub>2</sub>-adrenergic receptor activation enhances effector lymphocyte mobilization in humans and suppresses lymphoma growth in mice through NK-cells
Kyle A Smith, Helena Batatinha, Grace M Niemiro, et al.
Gynecologic Oncology
|
November 4, 2019
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial
D Lorusso, G Ferrandina, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 11, 2024
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study
D Lorusso, N Colombo, C Dubot, et al.
Gynecologic Oncology
|
May 24, 2001
Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer
H C Wagenaar, N Colombo, I Vergote, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours
A F Leary, M Quinn, K Fujiwara, et al.
ESMO Open
|
December 17, 2021
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study
J A Ledermann, B Zurawski, F Raspagliesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2022
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline
C Sessa, J Balmaña, S L Bober, et al.
Gynecologic Oncology
|
November 24, 2018
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12
F Heitz, P Harter, E Åvall-Lundqvist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 15, 2018
Safety and dose modification for patients receiving niraparib
J S Berek, U A Matulonis, U Peen, et al.
Page
of 22
Search research articles
Search
Showing results (191-200 of 219) with videos related to
Sort By:
Page
of 22
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2009
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
S Pecorelli, I Ray-Coquard, O Tredan, et al.
Brain, Behavior, and Immunity
|
May 1, 2025
Exercise-induced β<sub>2</sub>-adrenergic receptor activation enhances effector lymphocyte mobilization in humans and suppresses lymphoma growth in mice through NK-cells
Kyle A Smith, Helena Batatinha, Grace M Niemiro, et al.
Gynecologic Oncology
|
November 4, 2019
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial
D Lorusso, G Ferrandina, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 11, 2024
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study
D Lorusso, N Colombo, C Dubot, et al.
Gynecologic Oncology
|
May 24, 2001
Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer
H C Wagenaar, N Colombo, I Vergote, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours
A F Leary, M Quinn, K Fujiwara, et al.
ESMO Open
|
December 17, 2021
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study
J A Ledermann, B Zurawski, F Raspagliesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 2022
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline
C Sessa, J Balmaña, S L Bober, et al.
Gynecologic Oncology
|
November 24, 2018
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12
F Heitz, P Harter, E Åvall-Lundqvist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 15, 2018
Safety and dose modification for patients receiving niraparib
J S Berek, U A Matulonis, U Peen, et al.
Page
of 22